🔗 Permalink

Inventor profile of:

Francesca Schiaretti

City:

Parma

Country:

Italy

Published Applications:

Last publication date:

2021-06-17

Top Assignees for applications by Francesca Schiaretti

The entities that hold a legal rights for patent applications filed by inventor Schiaretti Francesca:

Chiesi Farmaceutici S.p.A. 16 Parma, Italy
CHIESI FARMMACEUTICI S.P.A. 1 Parma, Italy

Recent patent applications by Schiaretti Francesca

Francesca Schiaretti from Parma, IT has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2021-06-17

US20210177866A1

Human necessities

Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

#2 | 2020-11-26

US20200368252A1

Human necessities

Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

#3 | 2020-05-28

US20200163883A1

Human necessities

Carrier particles for dry powder formulations for inhalation

#4 | 2018-12-20

US20180360849A1

Human necessities

Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

#5 | 2018-11-22

US20180333359A1

Human necessities

Carrier particles for dry powder formulations for inhalation

#6 | 2018-11-15

US20180325816A1

Human necessities

Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

#7 | 2018-11-15

US20180325815A1

Human necessities

Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

#8 | 2018-05-17

US20180133161A1

Human necessities

USE OF MAGNESIUM STEARATE IN DRY POWDER FORMULATIONS FOR INHALATION

#9 | 2017-05-18

US20170136035A1

Human necessities

Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

#10 | 2016-09-15

US20160263027A1

Human necessities

Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

#11 | 2015-12-03

US20150342936A1

Human necessities

Dry powder formulation comprising a phosphodiesterase inhibitor

#12 | 2015-11-12

US20150320691A1

Human necessities

USE OF MAGNESIUM STEARATE IN DRY POWDER FORMULATIONS FOR INHALATION

#13 | 2015-01-15

US20150017248A1

Human necessities

Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

#14 | 2012-04-05

US20120082727A1

Human necessities

USE OF MAGNESIUM STEARATE IN DRY POWDER FORMULATIONS FOR INHALATION

#15 | 2012-02-09

US20120031403A1

Human necessities

Dry powder formulation comprising a phosphodiesterase inhibitor

#16 | 2011-12-22

US20110308519A1

Human necessities

DRY POWDER FORMULATION COMPRISING AN ANTIMUSCARINIC DRUG

InventorID:

1036090 ⎘